ReviewBest practice & research. Clinical haematology2013
Which donor or graft source should you choose for the strongest GVL? Is there really any difference.
Review in Best practice & research. Clinical haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.Bone marrow transplantation · 2015Trial
- Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.Bone marrow transplantation · 2026Article
- Review
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.Blood cancer journal · 2021Article
- Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.Pediatric transplantation · 2016Article
- A living band-aid for epidermolysis bullosa.Blood transfusion = Trasfusione del sangue · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.